What are the treatment options for a man with Gleason 4+3 (score 7) organ-confined prostate cancer?

Treatment of Gleason 4+3 (Score 7) Organ-Confined Prostate Cancer

For a man with Gleason 4+3 organ-confined prostate cancer, the primary treatment options are radical prostatectomy with extended pelvic lymph node dissection or external beam radiotherapy (76-78 Gy) combined with 4-6 months of androgen deprivation therapy (ADT). 1, 2

Risk Classification

Gleason 4+3=7 prostate cancer is classified as intermediate-risk disease based on the Gleason score of 7, regardless of PSA level or clinical stage. 1, 3 However, the predominance of Gleason pattern 4 (primary pattern 4) places this in the unfavorable intermediate-risk category, which has important treatment implications. 2

Primary Treatment Options

Option 1: Radical Prostatectomy (Preferred for Life Expectancy >10 Years)

Radical prostatectomy with extended pelvic lymph node dissection (ePLND) is recommended for patients with life expectancy exceeding 10 years. 1, 2

• Surgical approach: Perform ePLND if the predicted probability of lymph node involvement is ≥2%. 1 For intermediate-risk disease, ePLND should be performed in all patients undergoing lymph node dissection. 2

• Nerve-sparing considerations: Offer nerve-sparing surgery only to patients with low risk of extracapsular disease on that side. 2

• Timing: Surgery can safely be delayed for at least 3 months if needed. 2

• Margin status is critical: Positive surgical margins dramatically increase progression risk in Gleason 7 tumors (p<0.0001), more so than extent of extraprostatic extension. 4 Patients with positive margins or extracapsular extension should receive adjuvant radiotherapy. 2

Option 2: External Beam Radiotherapy + Short-Term ADT

Deliver intensity-modulated radiotherapy (IMRT) or volumetric-modulated arc therapy (VMAT) with image-guided radiotherapy (IGRT) to a total dose of 76-78 Gy combined with 4-6 months of neoadjuvant and concurrent ADT. 1, 2, 5

• Evidence base: Three randomized trials (RTOG 8610, TROG 9601, DFCI 95096) demonstrate cancer-specific survival benefit when short-term ADT is added to EBRT for intermediate-risk disease. 5

• ADT duration: 4-6 months is the standard recommendation for intermediate-risk disease. 1, 3, 2

• Dose escalation: Doses of 76-78 Gy (or 78-80 Gy when feasible) improve PSA-based disease control compared with lower doses. 5

• Focal boost option: When MRI identifies a dominant intraprostatic lesion, add a focal boost to conventional IMRT/IGRT (1.8-2.0 Gy per fraction). 2, 5

• Moderate hypofractionation alternative: 60 Gy in 20 fractions over 4 weeks or 70 Gy in 28 fractions over 6 weeks is an evidence-supported option that shortens treatment time. 2, 5

Option 3: Brachytherapy-Based Approaches

For patients with good urinary function and unfavorable intermediate-risk disease, offer low-dose-rate (LDR) or high-dose-rate (HDR) brachytherapy boost combined with IMRT/VMAT plus IGRT and 4-6 months of ADT. 2, 5

• Important caveat: LDR brachytherapy monotherapy shows inferior outcomes for tumors containing Gleason pattern 4 or 5 compared with combined EBRT or surgery. 5 Therefore, brachytherapy boost (not monotherapy) is the appropriate approach.

• Patient selection: Requires good baseline urinary function, no prior transurethral resection of the prostate (TURP), and appropriate prostate size. 5

Treatments NOT Recommended

Active Surveillance is NOT Appropriate

Active surveillance is not recommended for patients with Gleason 4+3 disease and life expectancy >10 years (Category 1 recommendation). 1

• The primary Gleason pattern 4 (4+3 vs 3+4) significantly impacts outcomes, with higher rates of extracapsular extension, seminal vesicle invasion, and positive margins. 6

• Active surveillance for Gleason 4+3 is associated with higher rates of clinical progression (22.9 vs 8.9 per 1,000 person-years) and metastatic disease (6.3 vs 2.4 per 1,000 person-years) compared with definitive treatment. 5

ADT Monotherapy is Insufficient

Androgen deprivation therapy alone does not improve survival and is not recommended for localized prostate cancer. 1

Cryotherapy and HIFU Not Standard

Cryotherapy, high-intensity focused ultrasound (HIFU), and focal therapy are not recommended as routine primary therapy due to lack of long-term comparative data. 1, 7, 2

Required Staging Workup

Before initiating definitive therapy, complete the following staging:

• Bone scintigraphy: Recommended if Gleason score is ≥4+3 or PSA ≥15 ng/mL. 8, 9

• Cross-sectional imaging: CT or MRI of abdomen and pelvis for nodal staging. 3, 9, 5

• Multiparametric MRI: For local staging and identification of dominant intraprostatic lesions (if not already performed). 5

• Advanced nodal imaging: Choline PET/CT or PSMA-PET/CT may be considered but should not deny radical local treatment if metastases are identified only on novel imaging. 9

Special Considerations for Life Expectancy <10 Years

For patients with life expectancy <10 years, options include observation, radiotherapy with or without 4-6 months ADT, or brachytherapy alone (for favorable factors only). 1

• Watchful waiting with delayed hormone therapy for symptomatic progression is appropriate for men not suitable for or unwilling to have radical treatment. 8, 7

Comparative Outcomes: Surgery vs. Radiation

Radiotherapy with ADT demonstrates superior 5-year PSA relapse-free survival (82.6%) compared to radical prostatectomy alone (55.4%, p<0.0001) for Gleason 7 disease. 10 However, this comparison did not account for appropriately used adjuvant radiotherapy after prostatectomy, which is now standard for high-risk pathologic features. 2

Critical Pitfalls to Avoid

• Do not confuse Gleason 3+4 with 4+3: The primary pattern matters significantly. Gleason 4+3 has worse prognosis and is NOT eligible for active surveillance. 1, 6

• Do not omit ADT with radiotherapy: Short-term ADT (4-6 months) with EBRT is a Category 1 recommendation for intermediate-risk disease and provides cancer-specific survival benefit. 1, 5

• Do not use brachytherapy monotherapy: For Gleason pattern 4 disease, brachytherapy should be combined with EBRT, not used alone. 5

• Do not skip extended lymph node dissection: If performing surgery with lymph node dissection, ePLND is required. 2